AGP Executive Report
Last update: 7 hours agoAI & Imaging: Midjourney’s $74M push to launch “whole-body” ultrasound screening has kicked off with big claims—and immediate radiology backlash. Trade & Drug Pricing: The US has opened a trade probe into Germany’s medicine pricing, arguing innovative drugs are undervalued and US patients pay more. Vaccines: FDA expanded Merck’s CAPVAXIVE pneumococcal vaccine indication for higher-risk children and teens (ages 2–17). Clinical Research: Updated RAMPART trial data show durvalumab monotherapy didn’t significantly improve DFS after RCC resection, while the combo arm previously did. Public Health Preparedness: India’s health authorities are stepping up vector-borne disease surveillance for an El Nino–linked rise in infections. Healthcare Access & Workforce: McLeod Health donated $150K to nursing programs, and a new government bone marrow transplant facility is set to open in Kolhapur. Equity & Outcomes: A study links structural racism and insurance disadvantage to more advanced breast cancer stage at diagnosis for Black women. MedTech Growth: India’s patent expiries could unlock $3–5B for local generics and biosimilars, while investors back more healthcare platforms and IPO plans.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![EU’s off-patent medicines industry calls for industrial strategy at Athens summit [Advocacy Lab]](https://www.euractiv.com/content/uploads/sites/2/2026/06/55326767888_13344cf508_k-e1781660333671.jpg)
